Is Empagliflozin a High-Alert (SHLT) Medication?
No, empagliflozin is not classified as a high-alert medication in the traditional sense (like insulin or sulfonylureas), but it does require specific safety monitoring for serious adverse events including euglycemic diabetic ketoacidosis, volume depletion, and genitourinary infections.
Key Safety Considerations
While empagliflozin does not carry the hypoglycemia risk that defines many high-alert diabetes medications, it has distinct safety concerns that warrant careful clinical attention:
Primary Safety Risks
Euglycemic Diabetic Ketoacidosis (DKA): This is the most serious risk, particularly in patients with poor food intake or insulin deficiency. The risk is rare in type 2 diabetes but requires immediate recognition and treatment 1. Discontinue empagliflozin 3-4 days before scheduled surgery, during critical illness, or during prolonged fasting 2.
Volume Depletion: Attention to volume status and blood pressure is essential, particularly when patients are ill or fasting. Adjust other volume-contracting agents as applicable and monitor kidney function upon initiation 2.
Genitourinary Infections: Increased risk of genital mycotic infections (mitigate with genital hygiene) and urinary tract infections. Rare but serious: necrotizing fasciitis of the perineum (Fournier gangrene) requires prompt treatment if suspected 2.
Comparison to Traditional High-Alert Diabetes Medications
Unlike sulfonylureas (which professional societies recommend against using in hospitals due to sustained hypoglycemia risk 1) or insulin, empagliflozin has:
- No hypoglycemia risk when used alone 2
- No requirement for dose titration based on glucose levels
- Different mechanism of adverse events (metabolic/infectious rather than hypoglycemic)
Hospital Use Considerations
Current guidelines do not recommend routine use of SGLT2 inhibitors in the hospital setting 1. A pilot randomized trial showed empagliflozin did not improve acute heart failure parameters (dyspnea, length of stay) compared to placebo, though it reduced a combined endpoint of worsening heart failure, rehospitalization, or death at 60 days 1.
When to Discontinue
- Before scheduled surgery (3-4 days prior)
- During critical illness
- During prolonged fasting or poor oral intake
- If DKA is suspected (evaluate and treat promptly)
- In patients at risk for volume depletion 2
Clinical Bottom Line
Empagliflozin is not a high-alert medication by standard definitions (which typically focus on drugs causing severe hypoglycemia or requiring intensive monitoring). However, it requires specific safety protocols around surgical procedures, sick days, and recognition of rare but serious complications like euglycemic DKA. The absence of hypoglycemia risk distinguishes it from traditional high-alert diabetes medications like insulin and sulfonylureas.